MX2019006220A - Ligandos opioides kappa de heteroaril fenoxi benzamida. - Google Patents

Ligandos opioides kappa de heteroaril fenoxi benzamida.

Info

Publication number
MX2019006220A
MX2019006220A MX2019006220A MX2019006220A MX2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A
Authority
MX
Mexico
Prior art keywords
disorder
kappa opioid
heteroarylphenoxy
benzamide
preparation
Prior art date
Application number
MX2019006220A
Other languages
English (en)
Inventor
Ian Montgomery Justin
Wayne Kauffman Gregory
Antonia Rankic Danica
Aaron Brodney Michael
Nelsen Rogers Bruce
Robert Verhoest Patrick
Kashmirilal Arora Kapildev
Francis Dunn Matthew
Eric Green Michael
Mariam KABLAOUI Natasha
Richard Mente Scot
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2019006220A publication Critical patent/MX2019006220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona compuestos de la Formula I: (ver fórmula) y sales farmaceuticamente aceptables de los mismos, en donde las variables R1, R2, R3, R4, R9, X, m y n son como se definen en la presente; procesos para la preparacion de; intermediarios utilizados en la preparacion de; y composiciones que contienen tales compuestos o sales; y sus usos para tratar trastornos asociados con opioides kappa (?-opioide) incluyendo, por ejemplo, un trastorno neurologico, o trastorno psiquiatrico tal como un trastorno neurocognitico, trastorno de abuso de sustancias, trastorno depresivo, trastorno de ansiedad, trastorno relacionado con trauma o estres y trastorno alimenticio.
MX2019006220A 2016-11-28 2017-11-27 Ligandos opioides kappa de heteroaril fenoxi benzamida. MX2019006220A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662426980P 2016-11-28 2016-11-28
US201762576435P 2017-10-24 2017-10-24
US201762585016P 2017-11-13 2017-11-13
PCT/IB2017/057418 WO2018096510A1 (en) 2016-11-28 2017-11-27 Heteroarylphenoxy benzamide kappa opioid ligands

Publications (1)

Publication Number Publication Date
MX2019006220A true MX2019006220A (es) 2019-10-07

Family

ID=60782279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006220A MX2019006220A (es) 2016-11-28 2017-11-27 Ligandos opioides kappa de heteroaril fenoxi benzamida.

Country Status (19)

Country Link
US (1) US10316021B2 (es)
EP (1) EP3544972B8 (es)
JP (1) JP7051853B2 (es)
CN (1) CN110234638B (es)
AU (1) AU2017365123B2 (es)
CA (1) CA3045242A1 (es)
DK (1) DK3544972T3 (es)
ES (1) ES2947293T3 (es)
FI (1) FI3544972T3 (es)
HR (1) HRP20230518T1 (es)
HU (1) HUE061945T2 (es)
IL (1) IL266962B (es)
MX (1) MX2019006220A (es)
PH (1) PH12019501172A1 (es)
PL (1) PL3544972T3 (es)
PT (1) PT3544972T (es)
RS (1) RS64258B1 (es)
TW (1) TWI720272B (es)
WO (1) WO2018096510A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018223177B2 (en) * 2017-02-24 2024-05-02 Xeniopro GmbH Aromatic compounds which enhance notch signaling, for use in therapy
WO2018154118A2 (en) * 2017-02-24 2018-08-30 Reinmueller Viktoria Novel aromatic compounds
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
EP3953361A1 (en) * 2020-04-05 2022-02-16 Pfizer Inc. Compounds and methods for the treatment of covid-19
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
TW202345795A (zh) * 2022-03-07 2023-12-01 美商健生醫藥公司 純質形式之結晶型阿替卡普蘭
TW202345796A (zh) * 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式
WO2024079733A1 (en) * 2022-10-12 2024-04-18 Adama Makhteshim Ltd. Process for the preparation of aminopyridazine derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6420415B1 (en) 1998-09-21 2002-07-16 Takeda Chemical Industries, Ltd. Thiol compounds, their production and use
JP2000159747A (ja) * 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
IT1303737B1 (it) 1998-11-11 2001-02-23 Smithkline Beecham Spa Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
DE60321207D1 (en) 2002-09-19 2008-07-03 Lilly Co Eli Diaryläther als opioid-rezeptor antagonisten
US7365209B2 (en) 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
ATE406360T1 (de) 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
TWI344955B (en) 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
JPWO2006088079A1 (ja) 2005-02-18 2008-07-03 日本曹達株式会社 有機無機複合体
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
ES2337622T3 (es) 2006-04-04 2010-04-27 Emodys Gmbh Uso de composiciones que contienen antagonistas del receptor opioide kappa para el tratamiento de trastornos disociativos.
EP2252581B1 (en) 2008-01-22 2012-06-20 Eli Lilly And Company Kappa selective opioid receptor antagonist
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
CR11559A (es) 2008-03-25 2010-10-20 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
US8048895B2 (en) 2008-04-18 2011-11-01 Research Triangle Institute Kappa opioid receptor ligands
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
WO2010080357A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
HN2010001319A (es) 2009-01-26 2013-01-15 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
CN104684894A (zh) 2012-10-02 2015-06-03 默克专利股份有限公司 吡咯烷类
WO2015109080A1 (en) 2014-01-15 2015-07-23 Research Triangle Institute Kappa-opioid receptor selective opioid receptor antagonists
US10118896B2 (en) 2014-11-26 2018-11-06 University Of Kansas Antagonists of the kappa opioid receptor

Also Published As

Publication number Publication date
US20180148432A1 (en) 2018-05-31
HUE061945T2 (hu) 2023-09-28
WO2018096510A1 (en) 2018-05-31
AU2017365123A1 (en) 2019-07-11
HRP20230518T1 (hr) 2023-08-04
JP2019535799A (ja) 2019-12-12
CN110234638A (zh) 2019-09-13
EP3544972B1 (en) 2023-04-26
US10316021B2 (en) 2019-06-11
CN110234638B (zh) 2022-10-21
JP7051853B2 (ja) 2022-04-11
CA3045242A1 (en) 2018-05-31
DK3544972T3 (da) 2023-05-30
TWI720272B (zh) 2021-03-01
AU2017365123B2 (en) 2022-02-17
TW201831460A (zh) 2018-09-01
IL266962A (en) 2019-07-31
FI3544972T3 (fi) 2023-06-02
PH12019501172A1 (en) 2019-12-11
IL266962B (en) 2022-02-01
ES2947293T3 (es) 2023-08-04
PL3544972T3 (pl) 2023-07-24
RS64258B1 (sr) 2023-07-31
EP3544972B8 (en) 2023-06-07
EP3544972A1 (en) 2019-10-02
PT3544972T (pt) 2023-06-20

Similar Documents

Publication Publication Date Title
PH12019501172A1 (en) Heteroarylphenoxy benzamide kappa opioid ligands
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2022001343A (es) Compuestos y composiciones para tratar trastornos hematologicos.
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MX2019012945A (es) Formas cristalinas de un compuesto inhibidor de jak.
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
JO2741B1 (en) Spiro-cyclic nitroblast as protease inhibitors
MX2018009659A (es) Proceso para preparar etilenaminas superiores y derivados de etilenaminas.
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
BR112016011016A8 (pt) derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica.
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2018005133A (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
MX2016008909A (es) Compuestos de isopropil triazolo piridina.
PH12019500822A1 (en) Crystalline forms of eravacycline
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
MX2021000226A (es) Nuevo proceso para la preparacion de diamidas antranilicas.
MX2020008465A (es) Clorhidrato de derivado de benzodiazepina y forma cristalina, método de preparación y aplicación del mismo.
PH12015502060A1 (en) Hydrochloride salts of an antibiotic compound